Easywell Biomedical (1799)

Currency in TWD
31.05
0.00(0.00%)
Delayed Data·
1799 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.4031.15
52 wk Range
27.6557.80
Key Statistics
Bid/Ask
16.10 / 16.15
Prev. Close
67.5
Open
30.8
Day's Range
30.4-31.15
52 wk Range
27.65-57.8
Volume
-
Average Volume (3m)
228.01K
1-Year Change
-44.849%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1799 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has fared poorly over the last month

Easywell Biomedical News & Analysis

Show more
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 13, 2026
EPS / Forecast
0.16 / --
Revenue / Forecast
236.7M / --
EPS Revisions
Last 90 days

1799 Income Statement

Compare 1799 to Peers and Sector

Metrics to compare
1799
Peers
Sector
Relationship
P/E Ratio
−73.0x0.0x−0.5x
PEG Ratio
45.270.000.00
Price/Book
5.3x0.0x2.6x
Price / LTM Sales
5.6x0.0x3.0x
Upside (Analyst Target)
-0.0%58.6%
Fair Value Upside
Unlock0.0%10.2%Unlock

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina; and TLX-011 for the treatment of inflammatory lesions of rosacea. It is also developing TLX-015, a medicine for the prevention and treatment of postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, a medication for adrenal insufficiency treatment; TLX-047, a systemic corticosteroid; HH-001, a sacubitril/valsartan sodium tablet; TLX-024, a liquid oral anticonvulsant; TLX-034, an endocrine drug; TWB-201, a Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company offers health food and products; and over-the-counter drugs. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.

FAQ

What Is the Easywell Biomedical (1799) Stock Price Today?

The Easywell Biomedical stock price today is 31.05 TWD.

What Stock Exchange Does Easywell Biomedical Trade On?

Easywell Biomedical is listed and trades on the Taipei Exchange.

What Is the Stock Symbol for Easywell Biomedical?

The stock symbol for Easywell Biomedical is "1799."

What Is the Easywell Biomedical Market Cap?

As of today, Easywell Biomedical market cap is 3.87B TWD.

What Is Easywell Biomedical's Earnings Per Share (TTM)?

The Easywell Biomedical EPS (TTM) is -0.42.

From a Technical Analysis Perspective, Is 1799 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Easywell Biomedical Stock Split?

Easywell Biomedical has split 7 times.

What is the current trading status of Easywell Biomedical (1799)?

As of Jun 17, 2026, Easywell Biomedical (1799) is trading at a price of 31.05 TWD, with a previous close of 67.50 TWD. The stock has fluctuated within a day range of 30.40 TWD to 31.15 TWD, while its 52-week range spans from 27.65 TWD to 57.80 TWD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.